Related Topics News -

     
 Detail   |   Print 
     
《大行》美銀證券:中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價
2026-08-12T  
《大行》野村升康龍化成目標價至32.2元 在手訂單推動全年收入預測上調
2026-07-27T  
《輪動華泰》黃金礦產股份造好 華虹昨彈18%
2026-07-22T  
中國上半年創新藥對外授權交易額逾1,000億美元 再創新高
2026-07-20T  
《大行》匯豐研究維持康龍化成「買入」評級 料CDMO增長強勁可抵銷外匯壓力
2026-07-16T  
《大行》康龍化成升逾5% 中銀國際:第二季盈利預告超預期 訂單兌現加快
2026-07-15T  
《大行》瑞銀:中國CRO行業上半年收入增長穩健 列藥明康德為首選
2026-07-14T  
《大行》瑞銀對CRO股份投資評級及目標價(表)
2026-07-14T  
《盈喜》康龍化成料中期純利按年增最多10%
2026-07-14T  
《大行》大和首次覆蓋康龍化成予「買入」評級 目標價25.5元
2026-07-08T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.